Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer
العنوان: | Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer |
---|---|
المؤلفون: | Michael Findlay, Ben Lawrence, Braden Woodhouse, Esther Coats, Papaarangi Reid, Mik Black, Masato Yozu, Kimiora Henare, Richard Babor, Jonathan Koea, Sean M. Grimmond, Nicole Kramer, Nicholas Knowlton, Kate Parker, Saxon Connor, Paula Shields, Dragan Damianovich, Cherie Blenkiron, Peter Johnston, Andrew D. MacCormick, Vicky Fan, Marianne S. Elston, Helen Morrin, Peter Tsai, Bridget A. Robinson, Richard W. Carroll, Christopher Jackson, Sandra Fitzgerald, Patrick Yap, Nooriyah Poonawala, Tamsin Robb, Cristin G. Print, Mee Ling Yeong, Sarah M James, Reena Ramsaroop, John A. Windsor, Adam Bartlett |
المصدر: | NPJ Genomic Medicine npj Genomic Medicine, Vol 3, Iss 1, Pp 1-12 (2018) |
بيانات النشر: | Cold Spring Harbor Laboratory, 2017. |
سنة النشر: | 2017 |
مصطلحات موضوعية: | 0301 basic medicine, lcsh:QH426-470, lcsh:Medicine, Aneuploidy, Neuroendocrine tumors, Gene mutation, medicine.disease_cause, Bioinformatics, Article, Loss of heterozygosity, 03 medical and health sciences, 0302 clinical medicine, Pancreatic cancer, Genetics, medicine, PTEN, MEN1, Folliculin, Molecular Biology, Genetics (clinical), Mutation, biology, lcsh:R, medicine.disease, lcsh:Genetics, 030104 developmental biology, 030220 oncology & carcinogenesis, DNA methylation, Cancer research, biology.protein |
الوصف: | Pancreatic neuroendocrine tumors (pNETs) are uncommon cancers arising from pancreatic islet cells. Here we report the analysis of gene mutation, copy number, and RNA expression of 57 sporadic well-differentiated pNETs. pNET genomes are dominated by aneuploidy, leading to concordant changes in RNA expression at the level of whole chromosomes and chromosome segments. We observed two distinct patterns of somatic pNET aneuploidy that are associated with tumor pathology and patient prognosis. Approximately 26% of the patients in this series had pNETs with genomes characterized by recurrent loss of heterozygosity (LoH) of 10 specific chromosomes, accompanied by bi-allelic MEN1 inactivation and generally poor clinical outcome. Another ~40% of patients had pNETs that lacked this recurrent LoH pattern but had chromosome 11 LoH, bi-allelic MEN1 inactivation, and universally good clinical outcome. The somatic aneuploidy allowed pathogenic germline variants (e.g., ATM) to be expressed unopposed, with RNA expression patterns showing inactivation of downstream tumor suppressor pathways. No prognostic associations were found with tumor morphology, single gene mutation, or expression of RNAs reflecting the activity of immune, differentiation, proliferative or tumor suppressor pathways. In pNETs, single gene mutations appear to be less important than aneuploidy, with MEN1 the only statistically significant recurrently mutated driver gene. In addition, only one pNET in the series had clearly actionable single nucleotide variants (SNVs) (in PTEN and FLCN) confirmed by corroborating RNA expression changes. The two clinically relevant patterns of LoH described here define a novel oncogenic mechanism and a plausible route to genomic precision oncology for this tumor type. Cancer: Frequent chromosome loss in rare pancreatic tumors The loss of entire chromosomes seems to be a fundamental driver of tumors arising from the hormone-producing cells of the pancreas. A team led by Cristin Print and Ben Lawrence from the University of Auckland, New Zealand, performed genomic and pathological analysis of 57 pancreatic neuroendocrine tumors, a rare form of cancer caused by the abnormal growth of hormone-producing islet cells within the pancreas. The researchers observed two distinct patterns of chromosome loss, with 26% of the samples missing one copy of 10 specific chromosomes and another 40% lacking a copy of chromosome 11. In both groups, the abnormal chromosome count prompts abnormal gene activity patterns, with recessive mutations unleashed and expressed unopposed. Single gene mutations seem to play only a minor role, suggesting that single gene-targeted drugs will provide little benefit in this disease setting, with more nuanced approaches required. |
اللغة: | English |
DOI: | 10.1101/214585 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b2b069f8a0a5bd4656fe386b2f1a809 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....9b2b069f8a0a5bd4656fe386b2f1a809 |
قاعدة البيانات: | OpenAIRE |
DOI: | 10.1101/214585 |
---|